New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive phenotype1 Phase III results published in ...

Patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) had slower rates of decline in lung function over 1 year when treated with nintedanib (Ofev), an intracellular ...

Please provide your email address to receive an email when new articles are posted on . New analyses of the INBUILD trial show nintedanib slowed lung function decline and reduced the annual rate of ...

Neil B. Minkoff, MD: We do have an FDA approved treatment option for chronic fibrosing ILD [interstitial lung disease], progressive phenotype. There are the antifibrotic medications pirfenidone and ...

Please provide your email address to receive an email when new articles are posted on . Treatment with nintedanib slowed the rate of interstitial lung disease progression in patients with chronic ...

The appraisal committee considered evidence submitted by Boehringer Ingelheim, a review of this submission by the evidence review group (ERG), NICE's technical report, and responses from stakeholders.

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other ...

New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs. Real-world data on usage of the tyrosine kinase inhibitor nintedanib (Ofev ...